Quick Answer
BIOCRYST PHARMACEUTICALS INC reported Total Assets of $514.16 million for the year ending 2025.
- BIOCRYST PHARMACEUTICALS INC showed an increase of +4.8% in Total Assets from 2024 to 2025.
- This data is from BIOCRYST PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2011: $108.41 million | Q3 2011: $92.51 million | Q1 2012: $80.09 million | Q2 2012: $76.24 million | Q3 2012: $64.09 million | Q1 2013: $46.90 million | Q2 2013: $39.92 million | Q3 2013: $53.21 million | Q1 2014: $43.39 million | Q2 2014: $141.98 million | Q3 2014: $137.13 million | Q1 2015: $129.87 million | Q2 2015: $150.18 million | Q3 2015: $138.96 million | Q1 2016: $102.88 million | Q2 2016: $82.22 million | Q3 2016: $91.50 million | Q1 2017: $129.51 million | Q2 2017: $113.51 million | Q3 2017: $191.49 million | Q1 2018: $155.37 million | Q2 2018: $136.64 million | Q3 2018: $168.31 million | Q1 2019: $142.34 million | Q2 2019: $116.34 million | Q3 2019: $90.50 million | Q1 2020: $136.59 million | Q2 2020: $214.71 million | Q3 2020: $176.23 million | Q1 2021: $284.43 million | Q2 2021: $277.28 million | Q3 2021: $265.76 million | Q1 2022: $527.72 million | Q2 2022: $510.54 million | Q3 2022: $558.59 million | Q1 2023: $509.74 million | Q2 2023: $529.89 million | Q3 2023: $522.92 million | Q1 2024: $467.89 million | Q2 2024: $472.42 million | Q3 2024: $491.25 million | Q1 2025: $480.05 million | Q2 2025: $457.19 million | Q3 2025: $446.42 million.
- Over the full 16 years of available data (2010 to 2025), BIOCRYST PHARMACEUTICALS INC's Total Assets has grown by 369.8%.
- Historical annual values: Fiscal year 2025: $514.16 million | Fiscal year 2024: $490.42 million | Fiscal year 2023: $516.96 million | Fiscal year 2022: $550.00 million | Fiscal year 2021: $588.15 million | Fiscal year 2020: $334.72 million | Fiscal year 2019: $175.28 million | Fiscal year 2018: $146.84 million | Fiscal year 2017: $178.26 million | Fiscal year 2016: $89.85 million | Fiscal year 2015: $122.36 million | Fiscal year 2014: $136.87 million | Fiscal year 2013: $48.87 million | Fiscal year 2012: $57.44 million | Fiscal year 2011: $82.21 million | Fiscal year 2010: $109.45 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: